

Market Announcement

17 March 2020

TBG Diagnostics Limited (ASX: TDL) – Trading Halt

Description

The securities of TBG Diagnostics Limited ('TDL') will be placed in trading halt at the request of TDL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 19 March 2020 or when the announcement is released to the market.

Issued by

Corey Lian

Adviser, Listings Compliance (Sydney)



ABN 82 010 975 612

Level 18, 101 Collins Street
Victoria 3000 Australia
Telephone: + 61 7 3273 9133
Facsimile: + 61 7 3375 1168
www.tbgbio.com

17 March 2020

Corey Lian
ASX Operations
Sydney NSW

Via Email

Dear Corey

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, TBG Diagnostics Limited (Company) requests a trading halt pending an announcement in relation to certification of a TBG Biotechnology Xiamen Inc Novel Coronavirus Diagnostic kit. The Company has a 46.65% ownership interest in TBG Biotechnology Xiamen.

The trading halt will remain in place until the earlier of the commencement of normal trading on Thursday 19 March 2020, or until the release of the announcement in respect of the above matter.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

Justyn Stedwell
Company Secretary